STOCK TITAN

Adia Med (ADIA) 10-Q Filings

ADIA OTC

Here are the 10-Q quarterly reports from Adia Med Inc (ADIA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-Q covers the quarterly report filed between annual reports, so if you follow ADIA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADIA filings page.

Rhea-AI Summary

Adia Med, Inc. (ADIA) reported third-quarter 2026 revenue of $454,385, versus $332,048 a year earlier, and nine-month revenue of $1,019,245 versus $521,958. It recorded a quarterly net loss of $53,015, compared with $70,376 net income, and a nine-month net loss of $271,922 versus $169,839. Nine-month operating cash use was $239,653.

ADIA disclosed substantial doubt about its ability to continue as a going concern, citing losses and dependence on higher revenue and outside capital. On September 30, 2026, ADIA and subsidiary Adia Labs agreed to sell 30% of Adia Labs to Live Oak Health LLC, doing business as QCM Biologics, for $1.5 million: $1 million cash and a $500,000 note. The buyer may purchase up to 10 more units at $50,000 each through September 30, 2028; if fully exercised and no other units are issued or transferred, ADIA would own 60%, with each side holding 50% of voting power.

The revised June 2026 statements reduce revenue and net income by $96,800 for the three- and six-month periods. Working capital was $128,369 at September 30, 2026.

Rhea-AI Summary

Adia Nutrition, Inc. focuses on AHSCT medical procedures for multiple sclerosis and biologic products through its Adia Med and Adia Labs segments. For the six months ended June 30, 2026, revenue rose to $661,660, mainly from medical procedures of $434,670 and biologics of $221,525, generating gross profit of $350,157.

The company still recorded a six‑month net loss of $122,107, though it achieved quarterly net income of $40,418 in the three months ended June 30, 2026. The balance sheet shows cash of $128,115, a related‑party line of credit balance of $835,312, an accumulated deficit of $16,095,589, and a stockholders’ deficit of $379,781. Management discloses “substantial doubt” about continuing as a going concern and expects to rely on increasing revenues and a $1,000,000 related‑party credit facility to fund operations.

Rhea-AI Summary

Adia Nutrition, Inc. reports sharply higher activity but continued losses for the three months ended March 31, 2026. Revenue rose to $176,275, mainly from medical procedures of MS patients and sales of biologics, producing gross profit of $67,577.

The company recorded a net loss of $162,525 and an accumulated deficit of $16,136,007, and its 10-Q states there is “substantial doubt” about its ability to continue as a going concern. Cash was $136,716 with total assets of $776,868 and total liabilities of $1,197,067, including a related-party line of credit of $723,656. As of March 31, 2026, 94,404,696 Class A common shares were outstanding.